Original Article
Adenanthin induces G2/M arrest and apoptosis in human non-small-cell lung cancer cells

Anbang Hu2*, Jinping Li2, Yulin Fang3, Weiqing Li1*

1Department of Traditional Chinese Medicine, Luohu District People’s Hospital, Shenzhen 518020, China;
2Department of Internal Medicine, Luohu District Chinese Medicine Hospital, Shenzhen 518021, China;
3Comprehensive Department of Affiliated Hospital of Jianghan University, Wuhan 430015, China. *Equal contributors.

Received August 2, 2018; Accepted October 10, 2018; Epub March 15, 2019; Published March 30, 2019

Abstract: Background: Non-small cell lung cancer (NSCLC) is a frequently encountered primary malignancy that is often immune to conventional chemotherapy. New chemotherapeutic agents are vital in combating this increasingly problematic disease. A natural diterpenoid derivative extracted from Isodon adenanthus leaves, adenanthin, has been demonstrated to produce anti-leukemic activity by acting on peroxiredoxin I/II. However, its role in NSCLC has yet to be fully investigated. Methods: Colony formation assays and CCK-8 assays were employed to investigate the growth of NSCLC cells and healthy cells. Induction of cellular apoptosis or arrest of cell cycles were determined by flow cytometric analysis, based on the Hoechst 33342 staining method or annexin V/propidium iodide. Intracellular levels of proteins related to apoptosis and the cell cycle were quantified via Western blot assay. A pan-caspase inhibitor, Z-VAD-FMK, allowed blockage of caspase activity in NSCLC (A549 and H460) cells, prior to treatment with adenanthin. Nude mice xenografts were created by subcutaneous inoculation, allowing researchers to study the in vivo effects of adenanthin (20 mg/kg, 40 mg/kg) on H460 cells. Apoptosis from mice tissues was observed by TUNEL assay. Pathological histology of tumor tissues was detected by H & E staining. Results: NSCLC cells (A549 and H460) were particularly sensitive to the effects of adenanthin. Adenanthin also conferred minimal cytotoxic damage to healthy cells. Adenanthin blocked NSCLC cell proliferation by arresting cell cycle progression in the G2/M phase and caspase3-dependent apoptosis. Adenanthin was able to attenuate tumor growth in mouse xenograft models while being well-tolerated, having an overall effect of prolonging mice survival. Conclusion: Adenanthin may serve as a novel anti-cancer agent that is potent and selective in eliminating NSCLC tumor cells.

Keywords: NSCLC, adenanthin, caspase3, apoptosis

Introduction

Lung malignancies have become increasingly common, worldwide. They confer a high rate of mortality and represent a primary cause of cancer-associated deaths in both genders across several countries [1]. Of all histological types, non-small cell lung cancer (NSCLC) represents the most numerous subtype, accounting for about 85% of all lung cancer cases [2]. The gold standard management regimen of NSCLC patients includes a combination of chemotherapy, radiotherapy, and surgery [3]. However, despite astounding developments in all three treatment modalities, patients with NSCLC still face a dismal five-year survival rate of less than 20% [4]. Part of the high mortality rate can be attributed to severe chemotherapeutic drug toxicity and resistance. Efforts to overcome these hurdles have given rise to biological agents that target specific molecules in the cancer cascade. For example, NSCLC patients that have epidermal growth factor receptor (EGFR) mutations are treated with tyrosine kinase inhibitors (TKIs) [5, 6]. However, overall patient survival still remains low.

Traditional Chinese herbal agents often consist of a number of natural compounds that are biologically active. These agents have been touted to possess impressive therapeutic efficacy accompanied by minimal adverse effects. These claims have fueled research in developing first-line chemotherapeutic agents based
Adenanthin inhibits non-small-cell lung cancer cell growth

on these compounds [7, 8]. Mechanistic insight has revealed that these agents are potent inducers of apoptosis and immune activation, both of which are thought to contribute to restriction of tumor growth [9, 10]. Adenanthin is a traditional Chinese herb, a diterpenoid compound isolated from leaves of *Isodon adenanthus*. Accumulating evidence has indicated that the *Isodon* species possesses a broad spectrum of pharmacological effects that includes antioxidant activity [11, 12], antibacterial infections [13], anti-inflammation [14], and anti-cancer activity [15]. Its bioactive components are known as diterpenoids [16], which are a large and structurally diverse class of secondary metabolites [17, 18]. Therefore, it is necessary and vital to explore the biological activities and underlying targets of diterpenoids. However, the underlying mechanisms of the natural compound adenanthin in its ability to inhibit human NSCLC cells and tumor bearing mice models have not yet been investigated.

Collectively, the present study demonstrates that NSCLC cells are especially vulnerable to the effects of adenanthin, in contrast to other types of cancer cells. Adenanthin induces apoptosis by inhibiting the caspase3-dependent pathway and stops cell proliferation by halting the cell at the G2/M phase of the cell cycle. Adenanthin can attenuate NSCLC cell growth *in vitro* as well as shrink xenograft tumors on mice models *in vivo*. These pre-clinical results document the potential anti-tumor properties of adenanthin in NSCLC.

### Materials and methods

#### Drugs and reagents

Adenanthin was purchased from Faces Biochemical Com., Ltd (Wuhan, Hubei, China; catalogue no. CFN99215) and stock solutions of 40 mM (20 mg/mL) were prepared by dissolving the compound in DMSO (Sigma-Aldrich, St. Louis, MO). HPLC analysis confirmed that its purity was at least 95%.

Rhodamine 123 and Hoechst 33342 were bought from Sigma-Aldrich (MO, USA). Cell Counting Kit-8 (CCK-8) and the Annexin V/PI apoptosis kits were procured from the Dojindo Laboratories (Japan) and Invitrogen (CA, USA), respectively. Antibodies against CDK2, Cyclin B1, and β-actin were bought from Epitomics (CA, USA). Ki67 antibodies were procured from Santa Cruz (CA, USA). Anti-Bcl-2, Bad, Bax, cl-caspase3 (Asp175), caspase3, cl-PARP, PARP, cytochrome C, and GAPDH were all obtained from Cell Signaling Technology (MA, USA). Terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) assay kit was obtained from Abcam (Cambridge, England). Chem Mate En Vision Kit was purchased from Dako (Glostrup, Denmark).

#### Cell lines and cell cultures

All three cell lines, BEAS-2B, H460, and A549, were obtained from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). A549 and H460 cells were cultured in DMEM medium (Gibco, NY, USA) and RPMI-1640 (Gibco, NY, USA), respectively. Both mediums were supplemented with 10% fetal bovine serum (Gibco) that contained 100 U/mL penicillin-streptomycin (Hyclone, UT, USA). BEAS-2B cells were grown in LHC-8 medium (Gibco, NY, USA) added with 1% epidermal growth factor (Hyclone, UT, USA) and 10% fetal bovine serum (Gibco). All cell lines were incubated at 37°C and 5% CO₂. Further explanations regarding other cell lines are disclosed in Additional File 1 (Supplementary Material and Methods).

#### Cell viability assay

Cell viability was quantified with the CCK-8 kit, in accordance with manufacturer instructions. Briefly, 96-well plates were utilized to seed cancer cells that were subsequently treated for 48 hours with adenanthin of increasing concentrations (0, 5, 10, 20, 40, 80, or 100 μM). Additionally, adenanthin was also administered at different time points (0, 24, 48, or 72 hours). CCK-8 solution was mixed in after the stipulated time periods and left to incubate with cancer cells for 4 hours. Cell survival percentages were quantified by SpectraMax 190 microplate reader (Molecular Devices) based on the absorbance.

#### Cell cycle and apoptosis analysis

The proportion of cells in each stage of the cell cycle was measured using propidium iodide (PI) staining assay. Cancer cells were harvested after being exposed to various concentrations
Adenanthin inhibits non-small-cell lung cancer cell growth

of adenanthin for 48 hours and fixed with 70% ethanol. Cells were subsequently centrifuged for 5 minutes at speeds of 3,000 rpm. Next, cells were incubated for 30 minutes with 100 mg/mL RNase in PBS at 37°C and stained with 50 mg/mL PI diluted in PBS. Cell Lab Quanta SC flow cytometer (Beckman Coulter, USA) was used to analyze cell cycle distribution.

The degree of cell apoptosis was analyzed using the Annexin V-FITC Apoptosis Detection Kit (BioVision). 5 × 10⁶ cells were first immersed in various concentrations of adenanthin. After 48 hours, cells were resuspended with 500 mL of binding buffer before being incubated with PI (5 mL) and Annexin V-fluorescein isothiocyanate (FITC; 5 mL). After 30 minutes, fluorescence-activated cell sorting (FACS) by flow cytometer (Becton Dickinson) was used to analyze cells. Cells that were only stained with Annexin V-FITC were interpreted as having gone through early apoptosis while cells that stained both with Annexin V-FITC and PI were combined for analysis.

Colony formation assay

Six-well plates were used to seed cancer cells at a density of 500 cells per well. All wells were given different concentrations of adenanthin (0 μM, 20 μM) and left for 48 hours [19]. Post-treatment, cells were left alone for one week to encourage colony formation. All cells were then fixed with 4% paraformaldehyde and subjected to 0.1% crystal violet staining. After staining, cells were subjected to three washings and air-drying before being quantified and photographed under a microscope (Leica, Germany).

Hoechst staining

Hoechst 33342 was used to identify morphological changes in nuclear organization for determining apoptotic cells, as described previously. Wavelengths of 490/540 nm were used to acquire cell images. The membrane potential of mitochondria was estimated by the relative ratio between the absorbance at 590 nm and 540 nm.

Mitochondrial membrane potential (ΔΨm) assay

Changes in mitochondrial membrane potential were determined by staining 20 μM adenanthin cells with JC-1. Changes were quantified using wavelengths of 490/540 nm. The mitochondrial membrane potential was derived from the ratio between 590 nm (red signal) and 540 nm (green signal).

Western blot analysis

Multiple concentrations of adenanthin (0 μM, 20 μM) were used to treat A549 and H460 cancer cells for 48 hours. Cell lysates were then prepared, followed by protein separation utilizing SDS-PAGE gel. Gel slices were then relocated onto polyvinylidene difluoride (PVDF) membranes (Millipore, Bedford, MA, USA). Blocking of endogenous reactions was done, followed by specific antibody probing. All membranes were then incubated with horseradish peroxidase-conjugated goat anti-Rabbit IgG after washing. They were visualized utilizing the enhanced chemiluminescent (ECL) detection reagent from Pierce (Rockford, IL, USA) [20].

Animal treatment with adenanthin

Six-week old 18 g nude mice were obtained from Shanghai SLAC Laboratory Animal (China). All animal experiments were carried out in strict compliance to the National Institutes of Health Guide for the Care and Use of Laboratory Animals, while experimental animal protocols were pre-approved by the Institutional Animal Care and Use Committee of Luohu District People's Hospital. Upon arrival at the facility, mice were initially reared in pathogen-free environment for one week. All mice received inoculation of 2 × 10⁶ H460 cells in 100 μl PBS at their left flank. The mice were then randomly grouped into three groups, consisting of 5 mice each, after one week. Each group received daily intraperitoneal injections of either PBS (control group), 20 mg/kg of adenanthin, or 40 mg/kg of adenanthin. After 4 weeks of treatment, all mice were anesthetized with isofluorane delivered by a R550 multi-channel small animal anesthesia machine (Ruiwode Lift Technology, Shenzhen, China) and sacrificed in a CO₂ chamber to harvest liver and tumor specimens, as well as weights of the tumors.

Immunohistochemistry

All tumors were sectioned into 4 mm-thicknesses before being formalin-fixed and embedded with paraffin. Antibodies against CKD2, Ki67,
Adenanthin inhibits non-small-cell lung cancer cell growth

and TUNEL were first used to stain slides prior to a second staining with secondary antibodies. Slides were then visualized with the ChemMate En Vision Kit (Dako, Glostrup, Denmark) and analyzed at ×400 magnification under a microscope. H & E staining was carried out for a few slides for histological analysis (Sigma-Aldrich, MO, USA). TUNEL assay was performed on selected slides, which were then subjected to in situ cell death detection analysis using a kit (Abcam, Cambridge, England).

Statistical analysis

All results are interpreted as mean ± S.D. Student’s t-test was used to detect significant differences between the two groups. All data was analyzed with the assistance of the SPSS program, version 18.0 (SPSS, Chicago, IL, USA). P value < 0.05 indicates statistical significance.

Results

Adenanthin possess potent tumor-eliminating properties and is extremely toxic to NSCLC cells

Adenanthin is an extract of Isodon adenanthus leaves and is a monomeric diterpenoid in nature (Figure 1A). Modern pharmacologic methods indicate that this compound is able to exert strong cytotoxic effects onto malignant cells. Present experiments comprised of a cell-based screening, aiming to investigate how adenanthin affected the viability of various types of healthy cells and tumor cells (Figure 1B). Nine human cancer cell lines and 7 healthy cell lines were incubated for 48 hours with increasing concentrations of adenanthin (0-400 μmol/L). CCK-8 assay evaluated the viability of the tested cells. Remarkably, adenanthin was able to inhibit the growth of human prostate, gallbladder, colon, gastric, liver, pancreatic, and cervical carcinoma cells at IC50 values ranging between 20 μmol/L to 200 μmol/L. NSCLC cells were noted to be exquisitely vulnerable to the deleterious effects of adenanthin. In contrast, adenanthin demonstrated comparatively reduced cytotoxicity in the presence of normal human bronchial epithelial cells (BEAS-2B), implying its selectivity for malignant cells.

Adenanthin inhibits NSCLC cell growth in both a dose-dependent and time-dependent manner

To measure adenanthin cytotoxicity on NSCLC cells, two human NSCLC cell lines (A549 and H460) and a normal human bronchial epithelial cell line (BEAS-2B) were exposed to different concentrations of adenanthin (0, 10, 20, 40, 80, or 100 μM) for varying durations (24, 48, or
Adenanthin inhibits non-small-cell lung cancer cell growth

72 hours). Subsequent CCK-8 assays revealed that adenanthin conferred its cytotoxic effects in a concentration- and time-dependent manner on multiple pancreatic cancer cell lines. In contrast, this compound had no marked effects on BEAS-2B cells (Figure 2A-D), further supporting the selectivity of adenanthin for malignant cells. From initial cytotoxicity results, this study selected the doses 0 and 20 μM of adenanthin to proceed with further colony formation assays (Figure 2E). Increasing adenanthin doses was demonstrated to reduce cell colony numbers (Figure 2F, 2G). Current data indicates that pancreatic cancer cells are affected by adenanthin in a time- and dose-dependent manner.

**Adenanthin induces G2/M phase cell cycle arrest in NSCLC cells**

To inspect whether adenanthin attenuates cell growth by interfering with cell cycle progression, cell distribution in the cell cycle was quantified, as well as related cell cycle checkpoint factors. Results revealed that a 48-hour treatment period with 20 mM adenanthin treatment led to an increased number of cells in the G1 phase (Figure 3A, 3B). Adenanthin treatment raised the population of G1 phase cell from 46.23% (control) to 58.67% in A549 cells and from 42.56% (control) to 55.16% in H460 cells, both of which translates to an approximate 1.3-fold increase. Additionally, Western blot analysis demonstrates that adenanthin treatment lowered expression of CDC25C, Cyclin B1, and CDK2 (Figure 3C). Taken together, adenanthin can carry out its anti-proliferative effects by halting cells in the G1 phase of the cell cycle.

**Adenanthin induces mitochondrial-related apoptosis in NSCLC cells**

This study evaluated the pro-apoptotic ability of adenanthin in NSCLC cells. Quantitative assessment of cell apoptosis was carried out using a dual-staining method with Annexin...
Adenanthin inhibits non-small-cell lung cancer cell growth

V-FITC and PI. Results revealed that a 48-hour treatment with 20 μM adenanthin was able to induce 14.65 ± 1.91% and 11.34 ± 2.36% apoptosis in A549 and H460 cells, respectively (Figure 4A). More extensive DAPI staining revealed nuclear fragmentation and condensation in the apoptotic cells (Figure 4B). This study further assessed changes in mitochondrial membrane potential (ΔΨm), bcl-2 family proteins, cytochrome c release, proteolytic cleavage of procaspase, and the general caspase inhibitor (z-VAD-fmk) rescue assay. ΔΨm reduction, as quantified by JC-1, was especially prominent in H460 cells that were exposed to 20 μM adenanthin (Figure 4C). z-VAD-fmk, an inhibitor of all cellular caspases, allowed researchers to determine if adenanthin also had the ability to block cell apoptosis through caspase-reliant methods. When z-VAD-fmk was added, the pro-apoptotic effects of adenanthin were attenuated, with only 3.53% of A549 cells shown to undergo apoptosis, compared to the previous value of 12.89%. Similarly, H460 cells underwent a decrease from 10.79 to 2.332% (Figure 4D). Protein quantifications of A549 and H460 cells treated with 20 μM adenanthin, according to Western blotting analysis, showed that both cells had markedly decreased bcl-2 levels, while having increased bax levels. Increased levels of cytochrome c and increased cleavage of cl-PARP and procaspase-3 were also noted, suggesting the ability of adenanthin to activate intrinsic apoptosis pathways (Figure 4E).

Adenanthin attenuated in vivo tumor growth in vivo

To assess the chemotherapeutic properties of adenanthin on growth of tumors in vivo, 2×10^6 A549 cells were injected subcutaneously in the left flank of nude mice. Following the initial dose, all mice were given either 20 or 40 mg/kg of intraperitoneal adenanthin for 21 days. Adenanthin was able to significantly attenuate tumor growth (Figure 5A, 5B). Tumor masses in either group that received adenanthin treatment were markedly shrunken, in contrast to the control group (Figure 5C). IHC analysis of antigen identified by monoclonal antibody...
Adenanthin inhibits non-small-cell lung cancer cell growth

(Ki67), which is associated with cellular proliferation, as well Cyclin-dependent kinase 2 (CDK2), were decreased in adenanthin-treated xenograft tumor tissues in addition to showing significantly fewer proliferative cells. Moreover, results of TUNEL assay revealed that TUNEL-positive cells were increased, indicating a higher proportion of apoptotic cells in adenanthin-treated tumors (Figure 5D). Furthermore, survival was remarkably prolonged in both adenanthin treatment groups (Figure 5E, P = 0.007). Body weights and general appearances of each mouse were regularly monitored during the experiment. Both general appearances and body weights of mice that received adenanthin treatment were maintained (Figure 5F).

In summary, adenanthin serves as an effective compound that can suppress the in vivo growth of xenograft NSCLC tumors with minimal toxicity.

Discussion

Although chemotherapy is the primary treatment modality for human cancers, broad adverse effects and occurrence of drug resistance are factors that significantly reduce the efficacy of these agents while severely impacting patient quality of life [21]. Pharmacologists and chemists have recently payed more attention in research concerning natural products, as they have rich structural diversity and have
been shown to possess promising therapeutic applications [22, 23]. This study aimed to identify medications that are novel, effective, and safe for further chemotherapeutic agent development. NSCLC cells lines H460 and A549 were demonstrated to be susceptible to adenanthin treatment, while healthy cells were spared from the compound’s toxicity. Similarly, both in vitro and in vivo models of NSCLC were vulnerable to reduction in growth when exposed to adenanthin, which imparts its cytotoxic effects by triggering arrest of cell progression at the G1 phase as well as by inducing caspase3-reliant cell death.

Cell cycle is responsible for dictating the proliferative fate of a cell and regulates complex processes that regulate cell division and growth [24]. Molecules regulating the movement of cells through this cell cycle are known as cyclins, which work by upregulating cyclin-dependent kinase (Cdk) enzymes [25]. Cells moving from the G2 to M phase are thought to be facilitated by the cyclin B1 protein [26]. The CDK2 protein also regulates cell cycle by forming a key role allowing cell transition to the S phase from the G1 phase. Downregulation of both of these proteins results in arrest in the G1 cell phase [27]. Several anti-cancer compounds carry out their effects by arresting cell cycle [28, 29]. The present study found that expression of Cdc25C, Cdk2, and Cyclin B1 were attenuated in NSCLC cells (Figure 3A, 3B), which may indicate the occurrence of cell cycle arrest in these types of malignant cells (Figure 3C).

Caspases are a family of proteolytic enzymes that function to mediate apoptosis via programmed cell death. Of these, caspase-3 is an intracellular protease that is critical in apoptosis and works early in the apoptotic process [30-32]. Quantifying caspase-3 activity allows reliable and accurate assessment of apoptosis [33]. Bcl-2 proteins are also critical in mediating apoptosis. This protein family includes anti-apoptotic (e.g., Bcl-2) and pro-apoptotic (e.g., Bax) factors [34]. Anti-apoptotic protein Bcl-2 controls apoptosis by influencing caspase-3-dependent pathways [35]. With decreased...
Adenanthin inhibits non-small-cell lung cancer cell growth

Bcl-2 and increased Bax, mitochondrion are stimulated to release cytochrome c, which in turn activates caspase-3, ultimately leading to apoptosis [34]. This study also revealed that adenanthin was able to suppress NSCLC cell growth through induction of caspase3-dependent apoptosis. After incubation with adenanthin, a dose-dependent decrease of cl-caspase3 was detected (Figure 4D, 4E). Moreover, the TUNEL assay, applied to test cell apoptosis in mice tumor tissues after adenanthin treatment (Figure 5D), revealed consistent in vitro results.

In summary, the current series of experiments highlight the biological mechanisms that underlie the cytotoxic effects of adenanthin in human NSCLC tumors. Both caspase3-mediated apoptosis and G1 phase cell cycle arrest were stimulated in the presence of adenanthin. Additionally, adenanthin markedly attenuated the in vitro and in vivo growth of NSCLC. Therefore, this study concludes that adenanthin may serve as a novel chemotherapeutic agent for management of NSCLC.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Weiqing Li, Department of Traditional Chinese Medicine, Luohu District People’s Hospital, Shenzhen, China. Tel: +86135 1082 2118; Fax: 021-51322118; E-mail: 755960096@qq.com

References


[29] Iness AN and Litovchick L. MuvB: a key to cell cycle control in ovarian cancer. Front Oncol 2018; 8: 223.


Supplementary Material and Method

HepG2, SGC-7901, SGC-996, PC3, cells were maintained in RPMI-1640 (Gibco, NY, USA) containing with 100 U/mL penicillin-streptomycin (Hyclone, UT, USA) and 10% fetal bovine serum (Gibco). MGC-803, Hela, HCT116, 293T, HL-7702, cells were cultured in DMEM medium (Gibco) containing 10% FBS. FHC, GES-1, IOSE144 cells were cultured in DMEM medium (Gibco) containing 10% FBS and 1% epidermal growth factor. HPDE cells were cultured in K-SFM medium (Gibco) containing 10% FBS and 1% epidermal growth factor. All cell lines were maintained at cell culture incubator with 37°C and 5% CO₂.